Manejo Clínico da Osteonecrose dos Maxilares Relacionada a Medicamentos Associada ao Ácido Zoledrônico em um Paciente com Mieloma Múltiplo: Relato de Caso
Conteúdo do artigo principal
Resumo
Detalhes do artigo

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their articles and grant the journal the right of first publication under the Creative Commons Attribution (CC BY) license, which allows others to share and adapt the work with proper attribution.
Referências
Guedes A, Becker RG, Teixeira LEM. Mieloma múltiplo (Parte 1): atualização sobre epidemiologia, critérios diagnósticos, tra-tamento sistêmico e prognóstico. Rev Bras Ortop. 2023;58(3):361-7. doi:10.1055/s-0043-1770149.
Gundesen MT, Schjesvold F, Lund T. Treatment of myeloma bone disease: when, how often, and for how long? J Bone Oncol. 2025;52:100680. doi:10.1016/j.jbo.2025.100680.
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820.
D’Souza J, Batstone M, Rogers S. Surgical challenges in the management of advanced osteoradionecrosis of the mandible. Austin J Otolaryngol. 2015;2(4):1037.
Kujanpää M, Vuollo V, Tiisanoja A, Laitala ML, Sándor GK, Karki S, Heikkinen AM, Snellman M, Richardson R, Ventä I. Incidence of medication-related osteonecrosis of the jaw and associated antiresorptive drugs in adult Finnish population. Sci Rep. 2025;15:17377. doi:10.1038/s41598-025-02225-2.
Frutuoso F, Freitas F, Vilares M, Francisco H, Marques D, Caramês J, Moreira A. Medication-related osteonecrosis of the jaw: a systematic review of case reports and case series. Diseases. 2024;12(9):205. doi:10.3390/diseases12090205.
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Sur-geons’ position paper on medication-related osteonecrosis of the jaws—2022 update. J Oral Maxillofac Surg. 2022;80(5):920-43. doi:10.1016/j.joms.2022.02.008.
Roman RC, Moldovan MA, Pop LS, Megieșan S, Faur CI. Platelet-rich fibrin treatment evaluation in patients with medica-tion-related osteonecrosis of the jaw and osteoradionecrosis. J Clin Med. 2024;13(12):3473. doi:10.3390/jcm13123473.
Maluf G, Caldas RJ, Fregnani ER, Santos PSS. Leukocyte- and platelet-rich fibrin as an adjuvant to the surgical approach for osteoradionecrosis: a case report. J Korean Assoc Oral Maxillofac Surg. 2020;46(2):150-4. doi:10.5125/jkaoms.2020.46.2.150.
Olofsson R, Korytowska M, Almhöjd U, Almståhl A, Cevik-Aras H. Oral health, dental treatment, and medication-related osteonecrosis of the jaw in multiple myeloma: a longitudinal cohort study. BMC Oral Health. 2024;24(1):184. doi:10.1186/s12903-024-03943-1.
American Association of Oral and Maxillofacial Surgeons. Medication-related osteonecrosis of the jaw – 2022 update [Internet]. Rosemont (IL): AAOMS; 2022 [cited 2026 May 19]. Available from: https://www.aaoms.org/docs/govt_affairs/advocacy_white_papers/mronj_position_paper.pdf
Silva PAB, Jaccoud ML, Silva MGB, Silva IS, Santos DCRF, Barros CRL, Oliveira LFS, Almeida Júnior AA. Osteonecrose man-dibular relacionada a medicamento. Braz J Implantol Health Sci. 2024;6(8):3033-41. doi:10.36557/2674-8169.2024v6n8p3033-3041.
Owosho AA, DeColibus KA, Levy LC, Okhuaihesuyi O. Management of medication-related osteonecrosis of the jaw in multiple myeloma patients with pentoxifylline and tocopherol: case reports. Case Rep Dent. 2025;2025:2765925. doi:10.1155/2025/2765925.
Srivastava A, Nogueras González GM, Geng Y, Won AM, Cabanillas ME, Naing A, Fu S, Piha-Paul SA, Janku F, Subbiah V. Prevalence of medication-related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer. 2021;29(5):2305-17. doi:10.1007/s00520-020-05881-0.
Ahdi HS, Wichelmann TA, Pandravada S, Ehrenpreis ED. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS). BMC Pharmacol Toxicol. 2023;24:15. doi:10.1186/s40360-023-00661-7.
Jian Y, Wang X, Liu H, Zhang Y, Li J, Zhao Q. Efficacy and safety of thalidomide for recurrent aphthous stomatitis: a systematic review and meta-analysis of randomized controlled trials. BMC Oral Health. 2024;24:49. doi:10.1186/s12903-024-04923-1.
Pinto Júnior VL, Santos PSS, Fregnani ER, Soares AB, Alves FA. Multiple-drugs-related osteonecrosis of the jaw in a patient with multiple myeloma: a case report. Int J Dent. 2023;2023:10137621. doi:10.1155/2023/10137621.
Dioguardi M, Troiano G, Lo Russo L, Giudice AM, Corsalini M, Murri Dello Diago A, Campanelli M, Cazzolla AP, Lo Muzio L. Differences in anatomical sites and gender in medication-related osteonecrosis of the jaw: a systematic review with me-ta-analysis. Front Oncol. 2023;13:1173305. doi:10.3389/fonc.2023.1173305.
Ko SY, Hwang TY, Baek K, Park CY. Incidence and severity of medication-related osteonecrosis of the jaw in patients with osteoporosis using data from a Korean nationwide sample cohort in 2002 to 2019: a retrospective study. J Yeungnam Med Sci. 2024;41(1):39-44. doi:10.12701/jyms.2023.01116.
Rugani P, Acham S, Kirnbauer B, Truschnegg A, Jakse N. Prevalence of medication-related osteonecrosis of the jaw in patients with breast cancer, prostate cancer, and multiple myeloma. Dent J (Basel). 2016;4(4):32. doi:10.3390/dj4040032.
Mikušková K, Hvizdoš D, Statelová D, Kovalová E, Kováčová V, Vargová L. Early surgical therapy for managing medica-tion-related osteonecrosis of the jaw in patients with osteoporosis. Bratisl Med J. 2025;126:3587-99. doi:10.1007/s44411-025-00403-2.
AlDhalaan NA, BaQais A, Al-Oma A. Medication-related osteonecrosis of the jaw: a review. Cureus. 2020;12(2). doi:10.7759/cureus.6944..
Preyra R, Jandhyala R, Yadavalli A, Varman M. Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: a systematic review and meta-analysis with active comparator disproportionality analysis. Br J Clin Pharmacol. 2025;91(3):1124-38. doi:10.1111/bcp.16211.
Inchingolo AM, Malcangi G, Ferrante L, Di Venere D, Netti A, Charitos IA, Scacco S, Inchingolo AD, Dipalma G, Bordea IR, Inchingolo F. MRONJ treatment strategies: a systematic review and two case reports. Appl Sci. 2023;13(7):4370. doi:10.3390/app13074370.
Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T. Medica-tion-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(2):117-35. doi:10.1016/j.oooo.2018.09.008.
Tetradis S, Allen MR, Ruggiero SL. Pathophysiology of medication-related osteonecrosis of the jaw: a minireview. JBMR Plus. 2023;7(8). doi:10.1002/jbm4.10785.
Fukuda H, Shibata T, Takeda Y, Tanaka A, Umeda M. Incidence and risk factors for medication-related osteonecrosis of the jaw in cancer patients treated with zoledronic acid: a retrospective study in Japan. Support Care Cancer. 2022;30(2):953-62. doi:10.1007/s00520-021-06731-2.
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23. doi:10.1002/jbmr.2405.
Wang Y, Xu Q, Li Y, Zhang H, Chen W, Liu X. Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease. Cancer Pathog Ther. 2024;3(1):280-92. doi:10.1016/j.cpt.2024.12.002.
López-Jornet P, Camacho-Alonso F, Molina-Miñano F, Gómez-García F. Use of leukocyte- and platelet-rich fibrin in medica-tion-related osteonecrosis of the jaw: a prospective study. J Oral Res. 2024;13(1):45-53. doi:10.17126/joralres.2024.005.
Adamska P, Stasiak P, Kobusińska N, Bartmański M, Zedler A, Studniarek M. Treatment of medication-related osteonecrosis of the jaw without and with the use of advanced platelet-rich fibrin: a retrospective clinical study. J Funct Biomater. 2025;16(5):180. doi:10.3390/jfb16050180.